Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study

杜皮鲁玛 医学 特应性皮炎 湿疹面积及严重程度指数 观察研究 内科学 回顾性队列研究 生活质量(医疗保健) 结节性痒疹 临床试验 皮肤病科 皮肤科生活质量指数 疾病 护理部
作者
Cataldo Patruno,Maddalena Napolitano,Giuseppe Argenziano,Ketty Peris,Michela Ortoncelli,Giampiero Girolomoni,Annamaria Offidani,Silvia Mariel Ferrucci,Giuseppe Fabrizio Amoruso,Mariateresa Rossi,Luca Stingeni,Giovanna Malara,Teresa Grieco,Caterina Foti,Massimo Gattoni,Camilla Loi,Michela Iannone,Marina Talamonti,Giuseppe Stinco,Franco Rongioletti
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:35 (4): 958-964 被引量:100
标识
DOI:10.1111/jdv.17094
摘要

BACKGROUND: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. METHODS: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
暴躁莹子发布了新的文献求助20
1秒前
2秒前
QIAN完成签到,获得积分10
2秒前
2秒前
0529完成签到,获得积分10
3秒前
无极微光的应助被恒驰采纳,获得20
3秒前
怡迦完成签到,获得积分10
3秒前
3秒前
3秒前
小瓜完成签到,获得积分10
4秒前
天天向上的应助被舒适的衣采纳,获得10
4秒前
科研通AI6.2的应助被小陈采纳,获得10
4秒前
yan发布了新的文献求助10
4秒前
TP完成签到,获得积分10
5秒前
5秒前
我是老大的应助被木子又又采纳,获得10
5秒前
科研通AI6.3的应助被xh采纳,获得10
5秒前
蚂蚁完成签到,获得积分10
5秒前
酷波er的应助被阿涛采纳,获得10
6秒前
微笑季节完成签到,获得积分10
6秒前
6秒前
6秒前
李昀睿完成签到,获得积分10
6秒前
7秒前
xucc发布了新的文献求助10
7秒前
awaiskhan发布了新的文献求助10
8秒前
绍兴大学完成签到,获得积分10
8秒前
普鲁斯特完成签到,获得积分10
8秒前
深情安青的应助被兴奋飞荷采纳,获得15
8秒前
9秒前
9秒前
9秒前
Ren的应助被daomaihu采纳,获得100
10秒前
10秒前
李昀睿发布了新的文献求助10
10秒前
科研努力完成签到,获得积分20
10秒前
10秒前
10秒前
繁荣的瑛的应助被崔正采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417